<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708149</url>
  </required_header>
  <id_info>
    <org_study_id>CCLin</org_study_id>
    <nct_id>NCT00708149</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial</brief_title>
  <official_title>Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lansoprazole administered nasogastrically
      is effective for stress ulcer prophylaxis in respiratory intensive care unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although stress ulcer is a complication that can cause mortality and morbidity in critical
      patients, there is still lack of consensus about its prophylaxis. There is also few data
      available from Taiwan. H2 blockers are commonly used due to convenience. Some prefer
      sucralfate (a mucosal protective agent) for the sake of less associated nosocomial pneumonia.
      Recently, proton pump inhibitors were shown to have good prophylactic effects for stress
      ulcer. Lansoprazole has good acid suppression effect and the tablets are soluble for the use
      of tube feeding. There was no data about the prophylaxis of stress ulcer development during
      the program of weaning from the mechanical ventilators. Therefore, we conduct a study of the
      comparison of lansoprazole administered nasogastrically and control group for stress ulcer
      prophylaxis in respiratory intensive care unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overt UGI bleeding: (1)tarry stool or coffee ground substance or fresh blood from NG≥ 60ml (2)blood component transfusion for more than PRBC 2 units 3)PES or TAE or surgical intervention for hemostasis</measure>
    <time_frame>The first 30 days after RCC admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 days mortality rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansprazole 30 mg qd from NG route or orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group without any PPI, H2 blockers or other medications for treating peptic ulcers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole OD</intervention_name>
    <description>arm 1: lansprazole 30 mg qd from NG route or orally for 14 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Takepron OD for PO QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>takepron placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Initial ICU admission, APACHE II score ≥25。

          2. Evidence of IICP ( ICP monitor proved or brain CT proved edema)。

          3. Evidence of peptic ulcer disease ( A or H) proved by PES more than 3 months ago
             without PPI or H2 blocker agents therapy in recent one week。

          4. UGI bleeding history in ICU before transferring to RCC (proved by NG aspirate coffee
             ground substance or fresh blood ≥ 60 ml)。Not received PPI or H2 blocker agents in
             recent one week.

          5. Received NSAID for more than 7 days。

          6. Bleeding tendency or with major disease patients: coagulopathy, ESRD (CCR&lt;10),
             hematologic malignancy, liver cirrhosis Child C。

        Exclusion Criteria:

          1. Age &lt; 18 y/o, pregnancy。

          2. Active UGI bleeding and under PPI or H2-blockers。

          3. Family unwillings。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chu C Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.e-pharm.info/index.php?option=com_content&amp;view=category&amp;id=38&amp;Itemid=103</url>
  </link>
  <reference>
    <citation>Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994 Feb 10;330(6):377-81.</citation>
    <PMID>8284001</PMID>
  </reference>
  <reference>
    <citation>Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004 Oct;32(10):2008-13.</citation>
    <PMID>15483408</PMID>
  </reference>
  <reference>
    <citation>Lam NP, Lê PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med. 1999 Jan;27(1):98-103.</citation>
    <PMID>9934901</PMID>
  </reference>
  <reference>
    <citation>Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997 Oct;54(4):581-96. Review.</citation>
    <PMID>9339962</PMID>
  </reference>
  <reference>
    <citation>Chun AH, Shi HH, Achari R, Dennis S, Cavanaugh JH. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther. 1996 Sep-Oct;18(5):833-42.</citation>
    <PMID>8930427</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>January 6, 2013</last_update_submitted>
  <last_update_submitted_qc>January 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lansoprazole, weaning,stress ulcer prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

